Skip to main content
. Author manuscript; available in PMC: 2021 Dec 23.
Published in final edited form as: J Pain Symptom Manage. 2021 Feb 20;62(3):e65–e74. doi: 10.1016/j.jpainsymman.2021.02.010

Table 3.

Decedents End-of-life Outcomes

Receiving Targeted Therapy N (%) Without Targetable Mutations N (%) OR 95% CI P
Patient received hospice services 15/21 (71.4) 79/95 (83.2) 0.43 0.14, 1.36 0.152
Hospitalization in last month of life 12/20 (60.0) 47/84 (56.0) 1.55 0.54, 4.43 0.414
Any cancer-directed therapy in last 14 days 10/22 (45.5) 5/94 (5.3) 14.98 4.08, 54.96 <0.001
Cytotoxic chemotherapy in last 14 days 3/22 (13.6) 4/94 (4.3) 3.01 0.59, 15.46 0.186
Death in the hospital 6/21 (28.6) 10/94 (10.6) 4.36 1.25, 15.21 0.021